Most cells produce latent transforming growth factor-beta 1 (TGF-β1), but only very few activate the cytokine via cell type-specific mechanisms. TGF-β1 favors cancer progression by suppressing anti-tumor T cell responses. Which cells produce this immunosuppressive TGF-β1 in human tumors is unknown. Putative sources include cells expressing the glycoprotein A repetitions predominant (GARP) protein, comprising mostly activated regulatory T cells (Tregs) (GARP(+)FOXP3(+) cells) and blood endothelial cells (BECs). We performed multiplexed immunohistofluorescence and computerized image analyses on 186 tumor samples from 5 cancer types (colorectal, urothelial, lung and breast primary carcinomas and melanoma metastases), compared to patient-matched adjacent non-cancerous tissues. GARP(+) Tregs were present in 29-75% of the various types of tumor samples. Their proportion was higher in tumors than non-cancerous tissues but unexpectedly it did not correlate with that of tumor-infiltrating T lymphocytes (TILs). The density of blood vessels was similar across samples, with more than half expressing GARP. The proportion of cells undergoing TGF-β1 signaling, which express the phosphorylated form of mothers against decapentaplegic homolog 2 (pSMAD2), was approximately twice as high in tumors compared to non-cancerous tissues. In most tumor types, pSMAD2(+) TILs were twice closer to the nearest FOXP3(+) cell than after random repositioning, at a distance (~â70 µm) consistent with short-range paracrine TGF-β1 signaling. In contrast, pSMAD2(+) non-T cells and pSMAD2(-) TILs were not closer to FOXP3(+) cells, neither were pSMAD2(+) cells (TILs and others) to BECs. We conclude that, in human tumors, GARP-expressing Tregs rather than BECs appear to represent a source of TGF-β1 suppressing nearby TILs. This local immunosuppression could be blocked with anti-GARP:TGF-β1 antibodies, particularly to treat patients with tumors heavily infiltrated by GARP-expressing Tregs.
GARP-expressing Tregs as a source of immunosuppressive TGF-β1 in human tumors.
阅读:3
作者:Van Meerbeeck Pierre, Maatougui Douae, de Streel Grégoire, Vaherto Noora, Marbaix Etienne, Aboubakar Nana Frank, Van den Eynde Marc, Devaux Alix, Carrasco Javier, Noel Agnès, van Baren Nicolas, Lucas Sophie
| 期刊: | Cancer Immunology Immunotherapy | 影响因子: | 5.100 |
| 时间: | 2025 | 起止号: | 2025 Sep 13; 74(10):308 |
| doi: | 10.1007/s00262-025-04157-2 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
